Satoshi Muto
Overview
Explore the profile of Satoshi Muto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
69
Citations
582
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Muto S, Takegami Y, Nakashima H, Mishima K, Kumagai H, Imagama S
Injury
. 2025 Mar;
56(4):112240.
PMID: 40088550
Introduction: Lisfranc joint injuries are a severe cause of disruption of foot stability and function, often requiring surgical intervention such as open reduction and internal fixation (ORIF). The necessity of...
2.
Matsumura Y, Inomata S, Yamaguchi H, Watanabe M, Ozaki Y, Muto S, et al.
Ann Thorac Surg Short Rep
. 2025 Jan;
1(1):91-93.
PMID: 39790544
An 18-year-old Japanese youth was transferred to our emergency department because of a traffic accident. He had a past history of total correction for tetralogy of Fallot as an infant....
3.
Muto S, Ozaki Y, Yamaguchi H, Watanabe M, Okabe N, Matsumura Y, et al.
Cancer Diagn Progn
. 2025 Jan;
5(1):32-41.
PMID: 39758230
Background/aim: Tumor intrinsic β-catenin signaling has been reported to influence the tumor immune microenvironment and may be a resistance mechanism to immune checkpoint inhibitors in various cancers. Patients And Methods:...
4.
Nomura K, Takada K, Kinoshita F, Muto S, Matsubara T, Kouki Y, et al.
Int J Cancer
. 2024 Nov;
156(7):1480-1491.
PMID: 39569608
The expression of programmed cell death-ligand 1 (PD-L1) and mutation in epidermal growth factor receptor (EGFR) are biomarkers used for perioperative treatment of lung adenocarcinoma. However, the clinical significance of...
5.
Muto S, Homma M, Kiko Y, Ozaki Y, Watanabe M, Okabe N, et al.
Oncol Rep
. 2024 Nov;
53(1).
PMID: 39513582
Lung cancer remains a leading cause of global cancer‑related deaths, therefore the identification of prognostic factors for lung cancer is critical. Casein kinase 2 alpha (CK2α) is one of the...
6.
Katayama Y, Yamada T, Tanimura K, Kawachi H, Ishida M, Matsui Y, et al.
Clin Cancer Res
. 2024 Nov;
PMID: 39495173
Purpose: Rearranged during transfection (RET) aberrations represent a targetable oncogene in several tumor types, with RET inhibitors displaying marked efficacy. However, some patients with RET-aberrant cancer are insensitive to RET...
7.
Sakaeda K, Kurose K, Matsumura Y, Muto S, Fukuda M, Sugasaki N, et al.
Cancer Treat Res Commun
. 2024 Jul;
40:100830.
PMID: 38964205
Background: NY-ESO-1 and XAGE1 cancer/testis antigens elicit humoral and cellular immune responses in NSCLC patients. We aimed to predict clinical benefit with ICI monotherapy, using an automated immunoassay of NY-ESO-1/XAGE1...
8.
Katsumata S, Shimokawa M, Hamada A, Haratake N, Nomura K, Fujino K, et al.
Eur J Cancer
. 2024 Feb;
201:113951.
PMID: 38417299
Objectives: To clarify the impact of central nervous system (CNS) metastasis on performance status (PS) at relapse, on subsequent treatment(s), and on survival of patients with lung adenocarcinoma harboring common...
9.
Ohkuma R, Miura S, Muto S, Toyomasu Y, Fujimoto Y, Ieguchi K, et al.
Front Immunol
. 2023 Oct;
14:1260492.
PMID: 37790929
Introduction: Programmed cell death ligand 1 (PD-L1) expression in tumor tissues is measured as a predictor of the therapeutic efficacy of immune checkpoint inhibitors (ICIs) in many cancer types. PD-L1...
10.
Takagi H, Muto S, Enta A, Fukuhara M, Asano S, Shio Y, et al.
Thorac Cancer
. 2023 Aug;
14(26):2707-2711.
PMID: 37545057
A patient presented with vomiting and gait disturbance. Investigation revealed a single cerebellar tumor and another tumor in the upper lobe of the left lung. Based on the severe vomiting...